title: Polyisoprenylation potentiates the inhibition of polyisoprenylated methylated protein methyl esterase and the cell degenerative effects of sulfonyl fluorides.
abstract: The polyisoprenylation pathway incorporates a reversible step that metabolizes polyisoprenylated methylated proteins from the ester to the carboxylate form. Polyisoprenylated protein methyl transferase (PPMTase) catalyses the esterification whereas polyisoprenylated methylated protein methyl esterase (PMPMEase) hydrolyzes them. Significant changes in the balance between the two enzymes may alter polyisoprenylated protein function possibly resulting in disease. Previous studies show that PMPMEase is the serine hydrolase, Sus scrofa carboxylesterase. Its susceptibility to the nonspecific serine hydrolase inhibitor, phenylmethylsulfonyl fluoride (PMSF) paved the way for its use as a prototypical compound to design and synthesize a series of putative high affinity specific inhibitors of PMPMEase. Pseudo first-order kinetics revealed an over 680-fold increase in k(obs)/[I] values from PMSF (6 M(-1)-1s(-1)), S-phenyl (L-50, 180 M(-1)s(-1)), S-benzyl (L-51, 350 M(-1)s(-1)), S-trans, trans-farnesyl (L-28, 2000 M(-1)s(-1)), to S-trans-geranylated (L-23, 4100 M(-1)s(-1)) 2-thioethanesulfonyl fluorides. C10 S-alkyl substitution revealed a k(obs)/[I] value (1800 M(-1)s(-1)) that was 298 times greater than that for PMSF. The compounds induced the degeneration of human neuroblastoma SH-SY5Y cells with EC(50) values of 49, 130 and >1000 µM for L-28, L-23 and PMSF, respectively. The increased affinity with the polyisoprenyl derivatization is consistent with the observed substrate specificity and the reported hydrophobic nature of the active site. These results suggest that (1) PMPMEase is a key enzyme for polyisoprenylated protein metabolism, (2) regulation of its activity is essential for maintaining normal cell viability, (3) abnormal activities may be involved in degenerative diseases and cancers and (4) its specific inhibitors may be useful in combating cancers.
authors: College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida 32307, USA.
authors: Byron
authors: B
authors: Aguilar
authors: Felix
authors: F
authors: Amissah
authors: Randolph
authors: R
authors: Duverna
authors: Nazarius S
authors: NS
authors: Lamango
references: Prog Neurobiol. 2000 May;61(1):61-74
references: 10759065
references: J Mol Biol. 2005 Sep 9;352(1):165-77
references: 16081098
references: Ann Neurol. 2006 Aug;60(2):197-203
references: 16802290
references: BMC Bioinformatics. 2008;9 Suppl 1:S16
references: 18315847
references: Cancer Cell. 2005 Apr;7(4):297-300
references: 15837619
references: J Biochem Mol Toxicol. 2005;19(5):347-57
references: 16292756
references: Neurology. 1999 Apr 22;52(7):1467-71
references: 10227636
references: J Biol Chem. 1995 Oct 13;270(41):24420-7
references: 7592656
references: Curr Top Med Chem. 2003;3(10):1075-93
references: 12769709
references: Science. 1993 Jan 15;259(5093):377-81
references: 8380507
references: Curr Drug Targets. 2005 May;6(3):301-23
references: 15857290
references: Neurosurgery. 1998 Jul;43(1):124-31; discussion 131-2
references: 9657198
references: J Mol Biol. 2006 Oct 13;363(1):201-14
references: 16962139
references: Biochemistry. 1985 Apr 9;24(8):2048-58
references: 3893542
references: Drug Metab Pharmacokinet. 2006 Jun;21(3):173-85
references: 16858120
references: J Biol Chem. 1974 Mar 25;249(6):1668-77
references: 4361818
references: Expert Opin Investig Drugs. 1997 Nov;6(11):1711-4
references: 15989575
references: Trends Mol Med. 2002 Jan;8(1):23-30
references: 11796263
references: Nat Rev Drug Discov. 2007 Jul;6(7):541-55
references: 17585331
references: FEBS Lett. 2001 Jun 8;498(2-3):197-200
references: 11412856
references: Arh Hig Rada Toksikol. 2007 Sep;58(3):355-8
references: 18050888
references: Nat Struct Biol. 2003 May;10(5):349-56
references: 12679808
references: Biochem Biophys Res Commun. 2003 Mar 28;303(1):1-7
references: 12646157
references: Arch Toxicol Suppl. 1997;19:325-9
references: 9079219
references: J Biochem Mol Toxicol. 2008 Feb;22(1):51-62
references: 18273909
references: Chem Rev. 2002 Dec;102(12):4639-750
references: 12475205
references: Front Biosci. 2007 May 01;12:4456-72
references: 17485388
references: J Toxicol Clin Toxicol. 2003;41(1):67-70
references: 12645970
references: Chem Biol Interact. 1999 May 14;119-120:513-7
references: 10421490
references: Ophthalmic Genet. 1996 Jun;17(2):43-6
references: 8832719
references: Anticancer Drugs. 2005 Jan;16(1):11-9
references: 15613899
references: Open Enzym Inhib J. 2009 Jan 1;2:12-27
references: 20664805
references: Mol Immunol. 1992 Jun;29(6):713-21
references: 1603092
references: J Nerv Ment Dis. 1978 Mar;166(3):222-5
references: 641541
references: Toxicol Lett. 2006 Mar 15;162(1):94-7
references: 16309859
references: Hematol Oncol Clin North Am. 2002 Oct;16(5):1065-88
references: 12512383
references: Toxicol Lett. 1995 Dec;82-83:459-63
references: 8597094